New Approaches in Breast Cancer Radiotherapy
- PMID: 38187103
- PMCID: PMC10765469
- DOI: 10.4274/ejbh.galenos.2023.2023-11-4
New Approaches in Breast Cancer Radiotherapy
Abstract
Breast cancer stands as the most prevalent malignancy, necessitating a well-established approach to its management due to its sustained prevalence over decades. The implementation of intensive treatments, combining various modalities, has yielded excellent survival outcomes. Consequently, the optimization of quality of life and the mitigation of long-term side effects emerge as critical considerations for clinicians. As a result, discussions regarding treatment de-intensification strategies have been initiated for all treatment modalities, including surgery, radiotherapy (RT), and chemotherapy. RT plays a crucial role in adjuvant therapy. The efficacy of RT in disease control and overall survival across all stages of breast cancer has been demonstrated in numerous clinical trials and meta-analyses utilizing extensive datasets. However, advancements in genetic tumor profiling and improved identification of disease subgroups have prompted a reevaluation of RT omission in low-risk groups as a strategy for treatment de-intensification. Conversely, technological improvements and shortened total treatment times with hypofractionation make RT a secure and feasible option for enhancing local control and survival with minimal impact on the quality of life.
Keywords: Breast cancer; oncotype Dx; radiotherapy; review.
©Copyright 2024 by the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.
Conflict of interest statement
Conflict of Interest: No conflict of interest was declared by the authors.
Similar articles
-
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1. Ont Health Technol Assess Ser. 2010. PMID: 23074401 Free PMC article.
-
The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.J Med Econ. 2023 Jan-Dec;26(1):973-990. doi: 10.1080/13696998.2023.2235943. J Med Econ. 2023. PMID: 37466220
-
Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?Genet Med. 2016 Aug;18(8):770-9. doi: 10.1038/gim.2015.173. Epub 2015 Dec 17. Genet Med. 2016. PMID: 26681310
-
Abbreviated course of radiotherapy (RT) for breast cancer.Breast. 2011 Oct;20 Suppl 3:S116-27. doi: 10.1016/S0960-9776(11)70308-3. Breast. 2011. PMID: 22015277 Review.
-
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis.Cancer Treat Rev. 2021 Sep;99:102254. doi: 10.1016/j.ctrv.2021.102254. Epub 2021 Jun 19. Cancer Treat Rev. 2021. PMID: 34242928
Cited by
-
A nomogram with Nottingham prognostic index for predicting locoregional recurrence in breast cancer patients.Front Oncol. 2024 Sep 16;14:1398922. doi: 10.3389/fonc.2024.1398922. eCollection 2024. Front Oncol. 2024. PMID: 39351357 Free PMC article.
-
Comparative Analysis of Dosimetry: IMRT versus 3DCRT in Left-Sided Breast Cancer Patients with Considering Some Organs in Out - of - Field Borders.Breast Cancer (Dove Med Press). 2024 Sep 5;16:567-582. doi: 10.2147/BCTT.S463024. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 39253547 Free PMC article.
-
Bridging Discoveries and Treatments: The New Landscape of Breast Cancer Research.Life (Basel). 2024 Jun 12;14(6):747. doi: 10.3390/life14060747. Life (Basel). 2024. PMID: 38929730 Free PMC article.
References
-
- Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–1716. - PMC - PubMed
-
- McGale P, Taylor C, Correa C, Cutter D, Duane F, et al; EBCTCG (Early Breast Cancer Trialists' Collaborative Group) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20- year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;384:1848. - PMC - PubMed
-
- Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, et al. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC Boost vs. No Boost trial: a randomized clinical trial. JAMA Oncol. 2017;3:42–48. - PubMed
-
- Morrow M, White J, Moughan J, Owen J, Pajack T, Sylvester J, et al. Factors predicting the use of breast- conserving therapy in stage I and II breast carcinoma. J Clin Oncol. 2001;19:2254–2262. - PubMed
-
- Hennequin C, Guillerm S, Quero L. Rationale for hypofractionation. Cancer Radiother. 2019;23:500–502. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials